Major depressive disorder (MDD) is a debilitating psychiatric condition characterized by a persistently low mood, a lack of ...
The largest and most ethnically diverse study of its kind has identified 697 genetic variants linked to major depressive disorder (MDD). The research also highlights potential therapies for ...
Incorporating dynamic pricing into cost-effectiveness analysis could offer significant benefits for equity in health care. The life cycle of a drug encompasses phases of market exclusivity, ...
Clinical data shows that BrainsWay’s new accelerated stimulation protocol is comparable to standard Deep TMS in depression score improvement, response and remission The accelerated protocol is now ...
Neumora Therapeutics is set to release data from the phase 3 KOASTAL-1 study using Navacaprant for the treatment of patients with MDD by the end of 2024; other data in 2025. Navacaprant showed ...
Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress BUOY-1 builds on successful ...
Patients who experienced a formulary-related rejection of cariprazine for adjunctive treatment of major depressive disorder had significantly higher hospitalization rates than those with approved ...
BURLINGTON, Mass. and JERUSALEM, Sept. 16, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (BWAY) (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback